Hamed Kamal's Form 4 filing
Spero Therapeutics, Inc. (SPRO) · filed Sep 15, 2023
- Accession no.
- 0000950170-23-048440
- Filed
- Sep 15, 2023
- Trade date
- Sep 13, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market sales total $50.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hamed KamalCIK 0001946366 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 13, 2023 | Common Stock | SSaleDisposed | −39,496 | $1.27 | −$50,159.92 | 576,461 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.